CDK4/6 inhibitors are routinely used and well tolerated in hormone receptor‐positive, HER2‐negative advanced breast cancer [56] and have been evaluated in a number of clinical trials recruiting patients with STS. The gene discussed is ERBB2; the disease is breast carcinoma.